JCO Early Release, published online ahead of print Nov 12 2007
Journal of Clinical Oncology, 10.1200/JCO.2007.12.1665
Received April 18, 2007
Accepted September 18, 2007
Cardiovascular Adverse Events During Adjuvant Endocrine Therapy for Early Breast Cancer Using Letrozole or Tamoxifen: Safety Analysis of BIG 1-98 Trial
Henning Mouridsen,* Aparna Keshaviah, Alan S. Coates, Manuela Rabaglio, Monica Castiglione-Gertsch, Zhuoxin Sun, Beat Thürlimann, Louis Mauriac, John F. Forbes, Robert Paridaens, Richard D. Gelber, Marco Colleoni, Ian Smith, Karen N. Price, and Aron Goldhirsch
From the Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation, Boston, MA; IBCSG Coordinating Center and Inselspital; Swiss Group for Clinical Cancer Research, Bern; Senology Center of Eastern Switzerland, Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; School of Public Health, University of Sydney, Sydney; Australian New Zealand Breast Cancer Trials Group, University of Newcastle, Calgary Mater Newcastle, Newcastle, New South Wales, Australia; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; Department of Medical Oncology, University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; European Institute of Oncology, Milan, Italy; and The Royal Marsden Hospital, London, United Kingdom.
* To whom correspondence should be addressed. E-mail: henning.mouridsen{at}rh.hosp.dk
Purpose: Previous analyses of adjuvant studies of aromatase inhibitors versus tamoxifen, including the Breast International Group (BIG) 1-98 study, have suggested a small numerical excess of cardiac adverse events (AEs) on aromatase inhibitors, a reduction in the incidence of hypercholesterolemia on tamoxifen, and significantly higher incidence of thromboembolic AEs on tamoxifen. The purpose of the present study is to provide detailed updated information on these AEs in BIG 1-98.
Patients and Methods: Eight thousand twenty-eight postmenopausal women with receptor-positive early breast cancer were randomly assigned (double-blind) between March 1998 and May 2003 to receive 5 years of adjuvant endocrine therapy with letrozole, tamoxifen, or a sequence of these agents. Seven thousand nine hundred sixty-three patients who actually received therapy are included in this safety analysis, which focuses on cardiovascular events. AE recording ceased 30 days after therapy completion (or after switch on the sequential arms).
Results: Baseline comorbidities were balanced. At a median follow-up time of 30.1 months, we observed similar overall incidence of cardiac AEs (letrozole, 4.8%; tamoxifen, 4.7%), more grade 3 to 5 cardiac AEs on letrozole (letrozole, 2.4%; tamoxifen, 1.4%; P = .001)—an excess only partially attributable to prior hypercholesterolemia—and more overall (tamoxifen, 3.9%; letrozole, 1.7%; P < .001) and grade 3 to 5 thromboembolic AEs on tamoxifen (tamoxifen, 2.3%; letrozole, 0.9%; P < .001). There was no significant difference between tamoxifen and letrozole in incidence of hypertension or cerebrovascular events.
Conclusion: The present safety analysis, limited to cardiovascular AEs in BIG 1-98, documents a low overall incidence of cardiovascular AEs, which differed between treatment arms.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
P. J. Barrett-Lee, J. M. Dixon, C. Farrell, A. Jones, R. Leonard, N. Murray, C. Palmieri, C. J. Plummer, A. Stanley, and M. W. Verrill
Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk
Ann. Onc.,
May 1, 2009;
20(5):
816 - 827.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Lenihan and F. J. Esteva
Multidisciplinary Strategy for Managing Cardiovascular Risks When Treating Patients with Early Breast Cancer
Oncologist,
December 1, 2008;
13(12):
1224 - 1234.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. K. Hernandez, H. T. Sorensen, J. Jacobsen, L. Pedersen, and T. L. Lash
Tamoxifen Treatment in Danish Breast Cancer Patients and 5-Year Risk of Arterial Atherosclerotic Events: A Null Association
Cancer Epidemiol. Biomarkers Prev.,
September 1, 2008;
17(9):
2509 - 2511.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. Giordano and G. N. Hortobagyi
Time to Remove the Subspecialty Blinders: Breast Cancer Does Not Exist in Isolation
J Natl Cancer Inst,
February 20, 2008;
100(4):
230 - 231.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Aebi and M. Rabaglio
Overview of Current Approaches to Adjuvant Endocrine Therapy
ASCO Educational Book,
January 1, 2008;
2008(1):
9 - 13.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
